市場調查報告書
商品編碼
966743

後天性血栓性血小板低下紫斑症:流行病學考察 (∼2030年)

Acquired Thrombotic Thrombocytopenic Purpura - Epidemiology Insight - 2030

出版日期: 按訂單生產 | 出版商: DelveInsight Business Research LLP | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供美國,歐洲5國(德國,西班牙,義大利,法國,英國)以及日本等7個主要市場後天性血栓性血小板低下紫斑症 (後天性TTP) 市場相關詳細說明,提供SWOT分析,疾病的風險與負擔,未滿足需求,高盛行率的的病例,診斷數·治療數等相關資訊。

目錄

第1章 重要考察

第2章 摘要整理

第3章 後天性血栓性血小板低下紫斑症:疾病的背景和概要

  • 簡介
  • 徵兆與症狀
  • 病理學
  • 危險因素
  • 診斷

第4章 患者治療過程

第5章 流行病學和患者人口

  • 流行病學的主要調查結果
  • 前提條件與理論的根據:主要7個國家
  • 流行病學方案:主要7個國家
    • 主要7個國家的後天性血栓性血小板低下紫斑症的流行病學方案
  • 美國的流行病學
    • 美國的後天性血栓性血小板低下紫斑症的流行病學方案
  • 歐洲5國的流行病學:各國
    • 德國的流行病學
    • 法國的流行病學
    • 義大利的流行病學
    • 西班牙的流行病學
    • 英國的流行病學
  • 日本的流行病學
    • 日本的後天性血栓性血小板低下紫斑症的流行病學方案

第6章 治療流程,目前治療,及醫療行為

  • 治療和管理
  • 治療流程

第7章 KOL的見解

第8章 未滿足需求

第9章 附錄

  • 參考文獻
  • 報告的調查手法

第10章 DelveInsight的服務內容

第11章 免責聲明

第12章 關於DelveInsight

目錄
Product Code: DIEI1018

DelveInsight's 'Acquired Thrombotic Thrombocytopenic Purpura - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Acquired Thrombotic Thrombocytopenic Purpura epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Acquired Thrombotic Thrombocytopenic Purpura Understanding

The DelveInsight Acquired Thrombotic Thrombocytopenic Purpura epidemiology report gives a thorough understanding of the Acquired Thrombotic Thrombocytopenic Purpura by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Acquired Thrombotic Thrombocytopenic Purpura in the US, Europe, and Japan. The report covers the detailed information of the Acquired Thrombotic Thrombocytopenic Purpura epidemiology scenario in seven major countries (US, EU5, and Japan).

Acquired Thrombotic Thrombocytopenic Purpura Epidemiology Perspective by DelveInsight

The Acquired Thrombotic Thrombocytopenic Purpura epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Acquired Thrombotic Thrombocytopenic Purpura epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Acquired Thrombotic Thrombocytopenic Purpura epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Acquired Thrombotic Thrombocytopenic Purpura Detailed Epidemiology Segmentation

The Acquired Thrombotic Thrombocytopenic Purpura epidemiology covered in the report provides historical as well as forecasted Acquired Thrombotic Thrombocytopenic Purpura epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Acquired Thrombotic Thrombocytopenic Purpura report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:

  • The Acquired Thrombotic Thrombocytopenic Purpura report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Acquired Thrombotic Thrombocytopenic Purpura Epidemiology Report and Model provide an overview of the risk factors and global trends of Acquired Thrombotic Thrombocytopenic Purpura in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Acquired Thrombotic Thrombocytopenic Purpura in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Acquired Thrombotic Thrombocytopenic Purpura
  • The report provides the segmentation of the Acquired Thrombotic Thrombocytopenic Purpura epidemiology

Report Highlights:

  • 11-Year Forecast of Acquired Thrombotic Thrombocytopenic Purpura epidemiology
  • 7MM Coverage
  • Total Cases of Acquired Thrombotic Thrombocytopenic Purpura
  • Total Cases of Acquired Thrombotic Thrombocytopenic Purpura according to segmentation
  • Diagnosed cases of Acquired Thrombotic Thrombocytopenic Purpura

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Acquired Thrombotic Thrombocytopenic Purpura?
  • What are the key findings pertaining to the Acquired Thrombotic Thrombocytopenic Purpura epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Acquired Thrombotic Thrombocytopenic Purpura across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Acquired Thrombotic Thrombocytopenic Purpura?
  • What are the currently available treatments of Acquired Thrombotic Thrombocytopenic Purpura?

Reasons to buy:

  • The Acquired Thrombotic Thrombocytopenic Purpura Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Acquired Thrombotic Thrombocytopenic Purpura market
  • Quantify patient populations in the global Acquired Thrombotic Thrombocytopenic Purpura market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Acquired Thrombotic Thrombocytopenic Purpura therapeutics in each of the markets covered
  • Understand the magnitude of Acquired Thrombotic Thrombocytopenic Purpura population by its epidemiology
  • The Acquired Thrombotic Thrombocytopenic Purpura Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Executive Summary of Acquired Thrombotic Thrombocytopenic Purpura

3. Acquired Thrombotic Thrombocytopenic Purpura : Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Sign and Symptoms
  • 3.3. Pathophysiology
  • 3.4. Risk Factors
  • 3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

  • 5.1. Epidemiology Key Findings
  • 5.2. Assumptions and Rationale: 7MM
  • 5.3. Epidemiology Scenario: 7MM
    • 5.3.1. Acquired Thrombotic Thrombocytopenic Purpura Epidemiology Scenario in the 7MM (2017- 2030)
  • 5.4. United States Epidemiology
    • 5.4.1. Acquired Thrombotic Thrombocytopenic Purpura Epidemiology Scenario in the United States (2017- 2030)
  • 5.5. EU-5 Country-wise Epidemiology
    • 5.5.1. Germany Epidemiology
      • 5.5.1.1. Acquired Thrombotic Thrombocytopenic Purpura Epidemiology Scenario in Germany (2017- 2030)
    • 5.5.2. France Epidemiology
      • 5.5.2.1. Acquired Thrombotic Thrombocytopenic Purpura Epidemiology Scenario in France (2017- 2030)
    • 5.5.3. Italy Epidemiology
      • 5.5.3.1. Acquired Thrombotic Thrombocytopenic Purpura Epidemiology Scenario in Italy (2017- 2030)
    • 5.5.4. Spain Epidemiology
      • 5.5.4.1. Acquired Thrombotic Thrombocytopenic Purpura Epidemiology Scenario in Spain (2017- 2030)
    • 5.5.5. United Kingdom Epidemiology
      • 5.5.5.1. Acquired Thrombotic Thrombocytopenic Purpura Epidemiology Scenario in the United Kingdom (2017-2030)
  • 5.6. Japan Epidemiology
    • 5.6.1. Acquired Thrombotic Thrombocytopenic Purpura Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

  • 6.1. Acquired Thrombotic Thrombocytopenic Purpura Treatment and Management
  • 6.2. Acquired Thrombotic Thrombocytopenic Purpura Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

  • 9.1. Bibliography
  • 9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

The table of contents is not exhaustive; will be provided in the final report

List of Tables

  • Table 1: Acquired Thrombotic Thrombocytopenic Purpura Epidemiology in 7MM (2017-2030)
  • Table 2: Acquired Thrombotic Thrombocytopenic Purpura Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Table 3: Acquired Thrombotic Thrombocytopenic Purpura Epidemiology in the United States (2017-2030)
  • Table 4: Acquired Thrombotic Thrombocytopenic Purpura Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5: Acquired Thrombotic Thrombocytopenic Purpura Epidemiology in Germany (2017-2030)
  • Table 6: Acquired Thrombotic Thrombocytopenic Purpura Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7: Acquired Thrombotic Thrombocytopenic Purpura Epidemiology in France (2017-2030)
  • Table 8: Acquired Thrombotic Thrombocytopenic Purpura Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9: Acquired Thrombotic Thrombocytopenic Purpura Epidemiology in Italy (2017-2030)
  • Table 10: Acquired Thrombotic Thrombocytopenic Purpura Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11: Acquired Thrombotic Thrombocytopenic Purpura Epidemiology in Spain (2017-2030)
  • Table 12: Acquired Thrombotic Thrombocytopenic Purpura Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13: Acquired Thrombotic Thrombocytopenic Purpura Epidemiology in the United Kingdom (2017-2030)
  • Table 14: Acquired Thrombotic Thrombocytopenic Purpura Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Table 15: Acquired Thrombotic Thrombocytopenic Purpura Epidemiology in Japan (2017-2030)
  • Table 16: Acquired Thrombotic Thrombocytopenic Purpura Diagnosed and Treatable Cases in Japan (2017-2030)

List of Figures

  • Figure 1: Acquired Thrombotic Thrombocytopenic Purpura Epidemiology in 7MM (2017-2030)
  • Figure 2: Acquired Thrombotic Thrombocytopenic Purpura Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Figure 3: Acquired Thrombotic Thrombocytopenic Purpura Epidemiology in the United States (2017-2030)
  • Figure 4: Acquired Thrombotic Thrombocytopenic Purpura Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5: Acquired Thrombotic Thrombocytopenic Purpura Epidemiology in Germany (2017-2030)
  • Figure 6: Acquired Thrombotic Thrombocytopenic Purpura Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7: Acquired Thrombotic Thrombocytopenic Purpura Epidemiology in France (2017-2030)
  • Figure 8: Acquired Thrombotic Thrombocytopenic Purpura Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9: Acquired Thrombotic Thrombocytopenic Purpura Epidemiology in Italy (2017-2030)
  • Figure 10: Acquired Thrombotic Thrombocytopenic Purpura Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11: Acquired Thrombotic Thrombocytopenic Purpura Epidemiology in Spain (2017-2030)
  • Figure 12: Acquired Thrombotic Thrombocytopenic Purpura Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13: Acquired Thrombotic Thrombocytopenic Purpura Epidemiology in the United Kingdom (2017-2030)
  • Figure 14: Acquired Thrombotic Thrombocytopenic Purpura Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Figure 15: Acquired Thrombotic Thrombocytopenic Purpura Epidemiology in Japan (2017-2030)
  • Figure 16: Acquired Thrombotic Thrombocytopenic Purpura Diagnosed and Treatable Cases in Japan (2017-2030)

The table of contents is not exhaustive; will be provided in the final report